Core Viewpoint - 康龙化成's stock increased by 4.33% on October 15, with a trading volume of 9.50 billion and a market capitalization of 557.46 billion [1] Company Overview - 康龙化成 (Beijing) New Drug Technology Co., Ltd. specializes in integrated drug research, development, and production services, covering the entire process from drug discovery to drug development [2][7] - The company's main revenue sources include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and other services [7] Financial Performance - For the first half of 2025, 康龙化成 achieved a revenue of 64.41 billion, representing a year-on-year growth of 14.93%, while the net profit attributable to shareholders decreased by 37.00% to 7.01 billion [8] - The company has distributed a total of 17.94 billion in dividends since its A-share listing, with 10.07 billion distributed in the last three years [9] Market Position and Trends - 康龙化成 is a leader in the CRO (Contract Research Organization) sector, providing comprehensive CRMO solutions for drug discovery and development, focusing on small molecule drug research [2] - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 84.95% of total revenue [3] Digital Transformation and Innovation - 康龙化成 has made significant progress in digital and intelligent construction within its clinical services, establishing a "Digital Innovation Technology Department" to enhance efficiency through AI and automation [3] - The integration of AI technology is expected to improve clinical service efficiency and reduce labor costs, although there may be risks related to management and technology integration [2][3]

Group 1 - The 2025 European Society for Medical Oncology (ESMO) will be held in Berlin from October 17 to 21, with expectations for new data on domestic innovative drugs and potential business development (BD) opportunities [1] - Chinese innovative drug companies are rapidly gaining global competitiveness, with a significant increase in licensing-out transactions, totaling nearly $66 billion in the first half of 2025, surpassing the $51.9 billion for the entire year of 2024 [1] - The impact of tariff policies on China's pharmaceutical industry is limited, as the market has already priced in the expectations regarding drug tariffs [1] Group 2 - As of October 15, 2025, the Hong Kong innovative drug ETF (513120) has risen by 1.69%, with notable increases in constituent stocks such as WuXi AppTec and Kelun-Biotech [2] - The Hong Kong innovative drug ETF (513120) has reached a new high in shares at 16.552 billion, with a total scale exceeding 22 billion yuan, making it the largest in the Hong Kong pharmaceutical ETF market [2] - The innovative drug ETF (515120) has also seen a rise of 2.40%, with significant growth in constituent stocks, and has experienced a notable increase in scale over the past three months [2] Group 3 - The Hong Kong innovative drug ETF (513120) closely tracks the CSI Hong Kong Innovative Drug Index, which has a high concentration of biopharmaceuticals and chemical pharmaceuticals, accounting for 92.5% [2] - The innovative drug ETF (515120) tracks the CSI Innovative Drug Industry Index, covering various aspects of innovative drug development, production, and sales [3] - Both ETFs support T+0 trading, enhancing liquidity and capital efficiency for investors [3]

Summary of CXO Industry Conference Call Industry Overview - The CXO industry is experiencing a marginal increase in domestic demand in Q2 2025, with leading indicators such as rising monkey prices and increased hiring validating the sustainability of order recovery, which is expected to drive price increases for CRO companies [1][2] - The overseas CDMO business is performing well, with an upward trend in small molecule orders and an increase in the number of effective Phase III clinical trials, indicating a positive outlook for small molecule CDMO orders over the next three years [1][4] Key Insights - The small molecule drug sector is being reassessed for its potential, with new technologies like molecular glue and ProTAC making previously non-druggable targets viable. This has led to significant production expansions in the second half of the year, with leading companies planning large-scale hiring [1][5] - The CDMO industry shows a strong growth trend, with high capacity utilization among leading companies and increased scheduling reflecting rising market demand. Price increases for monkeys in July and August 2025 indicate heightened demand for experimental animals [7] - Clinical trial activities are on the rise, with the number of newly announced clinical trials increasing by approximately 17% and 16% year-on-year in Q2 and Q3 2025, respectively. This trend is accompanied by a rise in CRO price discounts, alleviating budget pressures for biotech companies [8] Market Dynamics - The perception of the CXO industry has shifted significantly over the first three quarters of the year, with a focus on the recovery of overseas preclinical demand and the sustainability of performance for companies like WuXi AppTec [2] - The CRO sector is particularly focused on changes in demand from biotech companies, which have a high outsourcing ratio. Improved cash flow for large pharmaceutical companies positively impacts CRO business [10] - The small molecule drug demand is expected to be underestimated, with a notable increase in early pipeline activities transitioning to later stages, suggesting a substantial improvement in demand by 2026 [11] Future Outlook - There is optimism regarding potential price increases in Q4 2025 and a strong market performance anticipated for 2026, likely leading to further price hikes [12] - The impact of overseas policy uncertainties on the market is diminishing, with recent legislative proposals having limited actual effects on CRO companies [13] - The proposed 100% tariff on imported drugs by Trump is viewed as a negotiation tactic, with major pharmaceutical companies managing to secure favorable terms, thus limiting the proposal's market impact [14] Additional Considerations - The relationship between semaglutide and companies like WuXi AppTec is minimal, with potential indirect impacts on revenue from price fluctuations of related products. Current observations indicate no significant effects, but ongoing monitoring of government actions is advised [15][16]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） 中華人民共和國，北京 2025年10月14日 （股份代號：3759） 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 董事會會議通告 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2025年10月28日（星期二）舉行，藉以（其中包括）審議及批 准本公司及其附屬公司截至2025年9月30日止九個月之第三季度業績。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 樓柏良博士 ...

Core Viewpoint - 康龙化成 (03759.HK) will hold a board meeting on October 28, 2025, to review and approve the third-quarter results for the nine months ending September 30, 2025 [1] Group 1 - The board meeting is scheduled for October 28, 2025 [1] - The meeting will focus on the financial performance of the company and its subsidiaries [1] - The results to be reviewed will cover the period ending September 30, 2025 [1]

Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 董事會會議通告 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2025年10月28日（星期二）舉行，藉以（其中包括）審議及批 准本公司及其附屬公司截至2025年9月30日止九個月之第三季度業績。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 中華人民共和國，北京 2025年10月14日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 ...

Overview - The CRO industry in China has developed rapidly in recent years, particularly due to clear national pharmaceutical policies, accelerated medical reforms, and the expansion of the medical insurance market [1][9] - By 2024, the CRO market in China is expected to reach 89.22 billion yuan, with a year-on-year growth of 5.19%, and the clinical CRO market is projected to reach 46.31 billion yuan, growing by 4.68% [1][9] Industry Development - The CRO industry in China began in 1996 with the establishment of the first CRO company by MDS Pharmaceutical Services [5] - The industry has undergone significant changes, including a major reshuffle in 2015 due to quality concerns, leading to the elimination of many low-level CROs [5][10] - Major players like WuXi AppTec and Tigermed have gained competitive advantages through capital strength and project experience [5][10] Market Policies - The Chinese government has issued various policies to support the pharmaceutical manufacturing industry, encouraging new drug research and optimizing approval processes [6][7] Industry Chain - The CRO industry chain includes upstream components like experimental animals and biological reagents, midstream CRO companies, and downstream clients such as pharmaceutical companies and research institutions [8] - The pharmaceutical industry is the primary client for CROs, outsourcing clinical research to reduce costs and improve efficiency [8] Current Market Status - The global CRO market is projected to reach 90.03 billion USD in 2024, with a year-on-year growth of 9.65%, and the clinical CRO market is expected to reach 62.57 billion USD, growing by 8.35% [9] - The demand for high-quality medical resources is increasing, particularly in areas like rare diseases and public health events, driving the growth of the CRO market [9] Competitive Landscape - The CRO market in China is becoming increasingly competitive, with a notable shift towards Asia due to cost advantages and a large patient population [10] - Leading companies such as Tigermed and Kanglongda are recognized for their comprehensive clinical research services and have significant market shares [10][12] Future Trends - The quality management standards for drug development are expected to improve, leading to increased concentration in the industry as smaller CROs face challenges [13][14] - There will be a rise in specialized CROs focusing on specific disease areas, providing differentiated services to pharmaceutical companies [13][14]

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are Green Power Environmental (70.05%), China Telecom (69.96%), and COSCO Shipping Energy (68.73%) [1][2] - The companies with the largest increase in holding amounts over the last five trading days are Zijin Mining (+1 billion), Kuaishou (+0.981 billion), and Pop Mart (+0.624 billion) [1][2] - The companies with the largest decrease in holding amounts over the last five trading days are SMIC (-2.258 billion), Hua Hong Semiconductor (-1.222 billion), and Alibaba (-0.714 billion) [1][4] Hong Kong Stock Connect Holding Ratios - Green Power Environmental (01330) has a holding of 283 million shares, representing 70.05% [2] - China Telecom (00728) has a holding of 9.711 billion shares, representing 69.96% [2] - COSCO Shipping Energy (01138) has a holding of 891 million shares, representing 68.73% [2] - Other notable companies include Changfei Optical Fiber (06869) at 68.48% and China Shenhua (01088) at 67.25% [2] Recent Increases in Holdings - Zijin Mining (02899) saw an increase of 1 billion in holding amount, with a change of 29.19 million shares [2][4] - Kuaishou (01024) experienced an increase of 0.981 billion, with a change of 12.19 million shares [2][4] - Pop Mart (09992) had an increase of 0.624 billion, with a change of 2.39 million shares [2][4] Recent Decreases in Holdings - SMIC (00981) had a decrease of 2.258 billion in holding amount, with a change of 28.18 million shares [4] - Hua Hong Semiconductor (01347) saw a decrease of 1.222 billion, with a change of 13.86 million shares [4] - Alibaba (09988) experienced a decrease of 0.714 billion, with a change of 4.39 million shares [4]

Core Viewpoint - The Biotech Index (970038) closed at 2325.47 points, down 1.85%, with a trading volume of 31.496 billion yuan and a turnover rate of 2.07% [1] Group 1: Index Performance - On the day, 6 out of the index's constituent stocks rose, with Huace Testing leading with a 2.51% increase, while 44 stocks declined, with Boteng Co. leading the decline at 6.27% [1] - The top ten constituent stocks of the Biotech Index are primarily in the pharmaceutical and biotechnology sectors, with notable declines in major stocks like Mindray Medical and Changchun High-tech [1] Group 2: Stock Details - The top ten constituent stocks by weight include: - Mindray Medical (13.81% weight) at 235.20 yuan, down 2.81%, with a market cap of 285.166 billion yuan [1] - Changchun High-tech (5.41% weight) at 132.06 yuan, down 3.11%, with a market cap of 53.872 billion yuan [1] - Kanglong Chemical (4.66% weight) at 31.76 yuan, down 3.99%, with a market cap of 56.475 billion yuan [1] - Other notable stocks include Taige Pharmaceutical and Aimeike, both showing declines [1] Group 3: Capital Flow - The Biotech Index constituent stocks experienced a net outflow of 722 million yuan from main funds, while retail investors saw a net inflow of 534 million yuan [3] - Specific stocks like Mindray Medical and Changchun High-tech had varying levels of net inflow and outflow from different investor categories, indicating mixed investor sentiment [3]

Group 1 - Hong Kong's Hang Seng Index fell by 3.49%, down 916 points, closing at 25,373 points, while the Hang Seng Tech Index dropped by 4.54%. The morning trading volume reached HKD 281.8 billion [1] - Jinli Permanent Magnet (06680) surged over 12% as a rare earth giant announced price increases, with institutions optimistic about the strengthening strategic position of rare earths [1] - Semiconductor stocks rose against the trend, with Huahong Semiconductor (01347) increasing by 3.6%, driven by escalating competition in the technology sector and multiple catalysts for the semiconductor industry [1] - Kingsoft (03888) saw a rise of over 18% at one point, closing up over 9%, as external frictions escalate, highlighting the trend towards self-controlled industries and investment opportunities in the Xinchuang sector [1] - Gold stocks mostly rose due to risk aversion, with spot gold breaking through USD 4,060. Zijin Mining International (02259) increased by 4.6%, and Chifeng Jilong Gold Mining (06693) rose by 2.5% [1] Group 2 - MicroPort Scientific-B (02252) rose over 2% as its commercialization process accelerated, with overseas orders exceeding 60 units [2] Group 3 - Liqin Resources (02245) increased by over 5% following the implementation of cobalt export quotas in the Democratic Republic of Congo [3] - China Merchants Energy (01138) rose over 4% due to seasonal demand and event disturbances, with institutions expecting stronger freight rates [3] - Domestic insurance stocks fell across the board, with Tianan Insurance announcing a debt default of CNY 5.3 billion, which institutions suggest may mark the beginning of market-driven risk pricing. New China Life Insurance (01336) fell by 5%, China Pacific Insurance (02328) by 3.9%, and China Taiping Insurance (02601) by 3.6% [3] Group 4 - Pharmaceutical stocks continued their recent downward trend, with Junshi Biosciences (01877) dropping nearly 10.6% and Kanglong Chemical (03759) falling over 9% [4] Group 5 - Apple-related stocks experienced significant declines, with Hongteng Precision (06088) dropping over 10%, as institutions stated that the impact of tariffs on the supply chain should not be overestimated [5]